目的:评估宫内PRP对改善先前植入失败的妇女IVF结局的价值。
方法:Pubmed,WebofScience,和其他数据库从开始到2022年8月使用与\"富血小板血浆\"或\"PRP\"和\"IVF\"植入失败相关的关键字。“29项研究(3308名参与者)被纳入我们的分析,13个是RCT,6个是前瞻性队列,4个是预期的单臂,6项为回顾性分析。提取的数据包括研究的设置,研究类型,样本量,参与者的特征,路线,volume,PRP管理的时间安排,和结果参数。
结果:在6个RCT(886名参与者)和4个非RCT(732名参与者)中报告了植入率。比值比(OR)效应估计为2.62和2.06,95%CI分别为1.83、3.76和1.03-4.11。比较了4个RCT(307名参与者)和9个非RCT(675名参与者)的子宫内膜厚度,其平均差为0.93和1.16,分别为0.59-1.27和0.68-1.6595%CI。
结论:PRP给药可改善着床,临床妊娠,化学妊娠,正在怀孕,活产率,和子宫内膜厚度在以前植入失败的妇女。
OBJECTIVE: To assess the value of intrauterine PRP to improve IVF outcome in women with previous implantation failure.
METHODS: Screening of Pubmed, Web of Science, and other databases from inception to August 2022 using the keywords related to \"platelet-rich plasma\" OR \"PRP\" AND \"IVF\" \"implantation failure.\" Twenty-nine studies (3308 participants) were included in our analysis, 13 were RCTs, 6 were prospective cohorts, 4 were prospective single arm, and 6 were retrospective analyses. Extracted data included settings of the study, study type, sample size, participants\' characteristics, route, volume, timing of PRP administration, and outcome parameters.
RESULTS: Implantation rate was reported in 6 RCTs (886 participants) and 4 non-RCTs (732 participants). The odds ratio (OR) effect estimate was 2.62 and 2.06, with 95% CI of 1.83, 3.76, and 1.03-4.11, respectively. Endometrial thickness was compared in 4 RCTs (307 participants) and 9 non-RCTs (675 participants), which showed a mean difference of 0.93 and 1.16, with 0.59-1.27 and 0.68-1.65 95% CI, respectively.
CONCLUSIONS: PRP administration improves implantation, clinical pregnancy, chemical pregnancy, ongoing pregnancy, live birth rates, and endometrial thickness in women with previous implantation failure.